Results 161 to 170 of about 3,650 (207)

Toxicology of depot medroxyprogesterone acetate

Contraception, 1994
Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys.
openaire   +2 more sources

Bone mineral density and depot medroxyprogesterone acetate

Contraception, 2006
Depot medroxyprogesterone acetate (DMPA) suppresses pituitary gonadotrophin output, thus, suppressing ovulation. Estrogen production from the ovary is also strongly inhibited, and the resulting estrogen deficiency has a detrimental impact on bone.
Paola, Albertazzi, Mirella, Bottazzi, Susan A, Steel   +2 more
openaire   +2 more sources

Pharmacist-administered depot medroxyprogesterone acetate

Contraception, 2006
Continuation rates for women using depot medroxyprogesterone acetate (DMPA) for contraception in the United States are very low. Compliance/continuation rates at 3 months range from 57% to 71% with usual care and follow-up. At 6 months the range decreases to between 35% and 63%. The continuation rate at 1 year ranges from 23% to 45%.
openaire   +2 more sources

Urinary tract infection in the users of depot‐medroxyprogesterone acetate

Acta Obstetricia et Gynecologica Scandinavica, 2004
Background.  The effects of progesterone on muscle tone, peristalsis of the ureter and also urinary vasculature may cause urinary tract infection (UTI) in women who use depot‐medroxyprogesterone acetate (DMPA) for contraception.Methods.  In a cohort study, 200 women who chose DMPA for contraception were compared with 200 women who used the withdrawal ...
Saeideh, Ziaei, Mojgane, Ninavaei, Soghrate, Faghihzadeh   +2 more
openaire   +2 more sources

Reasons for discontinuation of depot medroxyprogesterone acetate

International Congress Series, 2004
Introduction: Approximately 16 million women worldwide use injectable contraceptive to regulate their fertility, 13 million women use depot medroxyprogesterone acetate (DMPA). Since 1996, DMPA has been used by several thousands of women in Iran. DMPA have some benefits such as highly efficacious in preventing pregnancy, increase hemoglobin levels, easy
Eftekharalsadat Hajikazemi, Soghra Nikpour, Hamid Haghani   +2 more
openaire   +1 more source

Depot Medroxyprogesterone Acetate and Adolescents

Clinical Journal for Nurse Practitioners in Women's Health
Depot medroxyprogesterone acetate (DMPA) is an effective method of contraception that may be underutilized due to lack of information or access. This article updates clinicians on current evidence about the safety and potential side effects of DMPA.
Eva Fried, Mandi Lew, Maria Mock
openaire   +1 more source

Bone mineral density in adolescent females using depot medroxyprogesterone acetate

Journal of Pediatric and Adolescent Gynecology, 2004
STUDY OBJECTIVE: To examine bone mineral density (BMD) on a semi-annual basis among control subjects and adolescent females receiving depot medroxyprogesterone acetate (DMPA) injection or oral contraceptives.
Eduardo Lara-Torre, S Paige Hertweck
exaly   +1 more source

Breast cancer and depot-medroxyprogesterone acetate: A review

Contraception, 1994
Depot-medroxyprogesterone acetate (DMPA) has been used world-wide since 1964 as a contraceptive in spite of the fact that it was only in 1992 licensed for contraceptive use in the USA due to concern about a possible breast cancer risk. Two recent studies have considered DMPA use and risk of breast cancer and these and earlier studies are reviewed here.
openaire   +2 more sources

Depot Medroxyprogesterone Acetate and Breast Cancer

JAMA, 1995
Background. —Although depot medroxyprogesterone acetate (DMPA) (Depo-Provera) has now been approved for marketing as a contraceptive in the United States, there are still unresolved issues about the relation between DMPA and risk of breast cancer. The two substantial case-control studies of this association yielded similar but inconclusive results ...
openaire   +1 more source

Depot Medroxyprogesterone Acetate or Oral Contraception in Postpartum Adolescents

Obstetrics & Gynecology, 1998
To compare rates of method continuation and repeat pregnancy among postpartum adolescents selecting depot medroxyprogesterone acetate or oral contraceptives (OCs).A retrospective study of 161 adolescents aged 19 years and younger who gave birth at an urban teaching hospital between May 1, 1994, and April 30, 1995, returned to the hospital's family ...
C M, O'Dell, C M, Forke, M M, Polaneczky, S J, Sondheimer, G B, Slap   +4 more
openaire   +2 more sources